Substance / Medication

Riluzole

Overview

Active Ingredient
riluzole
RxNorm CUI
35623

Indications

Riluzole tablets is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Labeler: AvKAREUpdated: 2026-01-15T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

6.1 [see Adverse Reactions ()] Riluzole tablets is contraindicated in patients with a history of severe hypersensitivity reactions to riluzole or to any of its components (anaphylaxis has occurred).

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The neuroprotective role of riluzole in spinal cord injury: a systematic review and meta-analysis.
Zarei Hamed, Khatami Seyedhesamoddin, Faghihi Mohammadsadegh et al. · Eur J Trauma Emerg Surg · 2025
PMID: 40615699Meta-Analysis
Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.
Kawashima Yoshitaka, Yamada Misa, Furuie Hiroki et al. · Neuropsychopharmacol Rep · 2023
PMID: 37463744Meta-AnalysisFull text (PMC)
Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Yao Ruzhan, Wang Haiquan, Yuan Mingqi et al. · Psychiatry Res · 2020
PMID: 31958711Meta-Analysis
Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature.
Srinivas Shanmukha, Wali Arvin R, Pham Martin H · Neurosurg Focus · 2019
PMID: 30835675Meta-Analysis
Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis.
de Boer J N, Vingerhoets C, Hirdes M et al. · Psychiatry Res · 2019
PMID: 31254879Meta-Analysis
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller Robert G, Mitchell J D, Moore Dan H · Cochrane Database Syst Rev · 2012
PMID: 22419278Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Riluzole (substance)
SNOMED CT
386980005
UMLS CUI
C0073379
RxNorm CUI
35623
Labeler
AvKARE

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.